Literature DB >> 23587957

Prevalence of β-lactamase-encoding genes among Enterobacteriaceae bacteremia isolates collected in 26 U.S. hospitals: report from the SENTRY Antimicrobial Surveillance Program (2010).

Mariana Castanheira1, Sarah E Farrell, Lalitagauri M Deshpande, Rodrigo E Mendes, Ronald N Jones.   

Abstract

Enterobacteriaceae bacteremia isolates (n = 195; 6.4% overall) collected from 26 U.S. hospitals located in 20 states were screened for various β-lactamase classes. A total of 175 isolates carried one to eight acquired β-lactamase genes of 44 types that were detected in 55 combinations. Eighty-five (43.6%) strains carried blaCTX-M, and blaCTX-M-15 was the most prevalent (33.8%). Genes encoding OXA-1/30 (often associated with blaCTX-M-15), CMY-2, SHV extended-spectrum β-lactamase (ESBLs), and TEM-1 were also prevalent. Among 33 carbapenem-resistant strains, 28 carried blaKPC-2 or blaKPC-3 (17 and 11 strains, respectively), and those were recovered mostly in the New York City area (16 strains) and Houston, TX (9 strains). Fourteen new SHV variants were identified among Klebsiella pneumoniae isolates carrying one or multiple SHV alleles, three carrying G238S and/or E240K amino acid alterations that confer ESBL activity. Only two of eight K. oxytoca isolates carried acquired β-lactamases, but most had mutations on the blaOXY promoter region, and three new OXY-encoding genes were characterized. Concordance between a commercial nucleic acid-based microarray (Check-MDR CT101) and reference methods was noted for 105/109 (97.2%) strains. Thirty-two strains having genes that are not targeted by the commercial system were detected (OXA ESBLs, PER, PSE, or intrinsic genes). Overall, a great variety of enzymes were observed, with numerous strains carrying multiple genes. Rates of CTX-M-producing strains appear to be increasing in U.S. hospitals (26.6% in 2007 to 43.8% for 2010) participating in the SENTRY Program. Furthermore, the Check-Points system seems to be a reliable, robust, and user-friendly assay for detection of enzyme-mediated resistance.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23587957      PMCID: PMC3697373          DOI: 10.1128/AAC.02252-12

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  20 in total

1.  bla(SHV) Genes in Klebsiella pneumoniae: different allele distributions are associated with different promoters within individual isolates.

Authors:  David S Hammond; Jacqueline M Schooneveldt; Graeme R Nimmo; Flavia Huygens; Philip M Giffard
Journal:  Antimicrob Agents Chemother       Date:  2005-01       Impact factor: 5.191

Review 2.  The CTX-M beta-lactamase pandemic.

Authors:  Rafael Cantón; Teresa M Coque
Journal:  Curr Opin Microbiol       Date:  2006-08-30       Impact factor: 7.934

Review 3.  Carbapenemases: the versatile beta-lactamases.

Authors:  Anne Marie Queenan; Karen Bush
Journal:  Clin Microbiol Rev       Date:  2007-07       Impact factor: 26.132

4.  Rapid emergence of blaCTX-M among Enterobacteriaceae in U.S. Medical Centers: molecular evaluation from the MYSTIC Program (2007).

Authors:  Mariana Castanheira; Rodrigo E Mendes; Paul R Rhomberg; Ronald N Jones
Journal:  Microb Drug Resist       Date:  2008-09       Impact factor: 3.431

5.  Escherichia coli sequence type ST131 as the major cause of serious multidrug-resistant E. coli infections in the United States.

Authors:  James R Johnson; Brian Johnston; Connie Clabots; Michael A Kuskowski; Mariana Castanheira
Journal:  Clin Infect Dis       Date:  2010-08-01       Impact factor: 9.079

6.  Identification of CTX-M beta-lactamases in Escherichia coli from hospitalized patients and residents of long-term care facilities.

Authors:  Carl Urban; Noriel Mariano; Patricia A Bradford; Margareta Tuckman; Sorana Segal-Maurer; Wehbeh Wehbeh; Louise Grenner; Rita Colon-Urban; Brian Johnston; James R Johnson; James J Rahal
Journal:  Diagn Microbiol Infect Dis       Date:  2010-04       Impact factor: 2.803

7.  Strength and regulation of the different promoters for chromosomal beta-lactamases of Klebsiella oxytoca.

Authors:  B Fournier; A Gravel; D C Hooper; P H Roy
Journal:  Antimicrob Agents Chemother       Date:  1999-04       Impact factor: 5.191

Review 8.  Extended-spectrum beta-lactamases: a clinical update.

Authors:  David L Paterson; Robert A Bonomo
Journal:  Clin Microbiol Rev       Date:  2005-10       Impact factor: 26.132

9.  First report of the emergence of CTX-M-type extended-spectrum beta-lactamases (ESBLs) as the predominant ESBL isolated in a U.S. health care system.

Authors:  James S Lewis; Monica Herrera; Brian Wickes; Jan E Patterson; James H Jorgensen
Journal:  Antimicrob Agents Chemother       Date:  2007-08-27       Impact factor: 5.191

Review 10.  AmpC beta-lactamases.

Authors:  George A Jacoby
Journal:  Clin Microbiol Rev       Date:  2009-01       Impact factor: 26.132

View more
  50 in total

1.  The Pandemic H30 Subclone of Sequence Type 131 (ST131) as the Leading Cause of Multidrug-Resistant Escherichia coli Infections in the United States (2011-2012).

Authors:  James R Johnson; Stephen Porter; Paul Thuras; Mariana Castanheira
Journal:  Open Forum Infect Dis       Date:  2017-05-02       Impact factor: 3.835

2.  Antimicrobial Activity Evaluation of Tebipenem (SPR859), an Orally Available Carbapenem, against a Global Set of Enterobacteriaceae Isolates, Including a Challenge Set of Organisms.

Authors:  S J Ryan Arends; Paul R Rhomberg; Nicole Cotroneo; Aileen Rubio; Robert K Flamm; Rodrigo E Mendes
Journal:  Antimicrob Agents Chemother       Date:  2019-05-24       Impact factor: 5.191

3.  Ceftaroline activity against bacterial pathogens frequently isolated in U.S. medical centers: results from five years of the AWARE surveillance program.

Authors:  Helio S Sader; Robert K Flamm; Jennifer M Streit; David J Farrell; Ronald N Jones
Journal:  Antimicrob Agents Chemother       Date:  2015-02-02       Impact factor: 5.191

4.  In Vitro Activity of Ceftazidime-Avibactam against Isolates from Respiratory and Blood Specimens from Patients with Nosocomial Pneumonia, Including Ventilator-Associated Pneumonia, in a Phase 3 Clinical Trial.

Authors:  Gregory G Stone; Patricia A Bradford; Margaret Tawadrous; Dianna Taylor; Mary Jane Cadatal; Zhangjing Chen; Joseph W Chow
Journal:  Antimicrob Agents Chemother       Date:  2020-04-21       Impact factor: 5.191

5.  Ceftazidime-avibactam activity tested against Enterobacteriaceae isolates from U.S. hospitals (2011 to 2013) and characterization of β-lactamase-producing strains.

Authors:  Mariana Castanheira; Janet C Mills; Sarah E Costello; Ronald N Jones; Helio S Sader
Journal:  Antimicrob Agents Chemother       Date:  2015-04-06       Impact factor: 5.191

6.  Rapid testing using the Verigene Gram-negative blood culture nucleic acid test in combination with antimicrobial stewardship intervention against Gram-negative bacteremia.

Authors:  Jacqueline T Bork; Surbhi Leekha; Emily L Heil; LiCheng Zhao; Rilwan Badamas; J Kristie Johnson
Journal:  Antimicrob Agents Chemother       Date:  2014-12-29       Impact factor: 5.191

7.  Epidemiology and clinical outcomes of patients with carbapenem-resistant Klebsiella pneumoniae bacteriuria.

Authors:  Zubair A Qureshi; Alveena Syed; Lloyd G Clarke; Yohei Doi; Ryan K Shields
Journal:  Antimicrob Agents Chemother       Date:  2014-03-17       Impact factor: 5.191

8.  A statistical approach for determination of disk diffusion-based cutoff values for systematic characterization of wild-type and non-wild-type bacterial populations in antimicrobial susceptibility testing.

Authors:  Giorgia Valsesia; Malgorzata Roos; Erik C Böttger; Michael Hombach
Journal:  J Clin Microbiol       Date:  2015-03-11       Impact factor: 5.948

9.  Recent Emergence of Escherichia coli with Cephalosporin Resistance Conferred by blaCTX-M on Washington State Dairy Farms.

Authors:  Margaret A Davis; William M Sischo; Lisa P Jones; Dale A Moore; Sara Ahmed; Diana M Short; Thomas E Besser
Journal:  Appl Environ Microbiol       Date:  2015-04-24       Impact factor: 4.792

Review 10.  Beyond Susceptible and Resistant, Part III: Treatment of Infections due to Gram-Negative Organisms Producing Carbapenemases.

Authors:  Navaneeth Narayanan; Linda Johnson; Conan MacDougall
Journal:  J Pediatr Pharmacol Ther       Date:  2016 Mar-Apr
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.